Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Looking for some input to pricing model for this stock based upon approval

Just out of interest did any note this inthe newletter from Griffin Security. 01 May 2012 document contained their previous and current opinions as below:

2/24/2012 – Updating Coverage: share price: $2.35; rating: BUY; 12-month price target:
$14.00;

5/1/2012 – Updating Coverage: share price: $2.24; rating: BUY; 12-month price target: $14.00.

Are these guys just contrarians or are they in the ballpard once the Partner or FDA issues are resolved?

OOG

Share
New Message
Please login to post a reply